ERBB2 and breast cancer: Building on these findings, our study utilized DCE‐MRI‐based ViT models and achieved robust and substantial performance, especially in distinguishing HER2‐low from HER2‐positive breast cancers, likely due to the ViT's advanced feature extraction capabilities, which leverage self‐attention mechanisms to capture both global and local imaging patterns.